Bicara Therapeutics Inc. Increase Decrease In Operating Lease Liability
Bicara Therapeutics Inc. (BCAX) reported Increase Decrease In Operating Lease Liability of -$547.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Bicara Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$277.00K.
- Bicara Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$270.00K.
- Bicara Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$292.00K, a 200.00% decline year-over-year.
- Bicara Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$317.00K.
- Bicara Therapeutics Inc. increase decrease in operating lease liability for fiscal 2025 was -$932.00K, a 1250.62% decline from fiscal 2024.
- Bicara Therapeutics Inc. increase decrease in operating lease liability for fiscal 2024 was $81.00K.
- Bicara Therapeutics Inc. increase decrease in operating lease liability for fiscal 2023 was -$47.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$547.00K 10-Q · filed 2026-08-11 | -$839.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$270.00K 10-Q · filed 2026-05-11 | -$562.00K derived: sum of 2 quarters · filed 2026-05-11 | -$879.00K derived: sum of 3 quarters · filed 2026-05-11 | -$1.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$609.00K derived: sum of 2 quarters · filed 2026-03-30 | -$785.00K derived: sum of 3 quarters · filed 2026-08-11 | -$932.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$317.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$493.00K derived: sum of 2 quarters · filed 2026-08-11 | -$640.00K 10-Q · filed 2025-11-10 | -$348.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$323.00K 10-Q · filed 2026-08-11 | -$31.00K derived: sum of 3 quarters · filed 2026-08-11 | -$103.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$147.00K 10-Q · filed 2026-05-11 | $145.00K derived: sum of 2 quarters · filed 2026-05-11 | $73.00K derived: sum of 3 quarters · filed 2026-05-11 | $2.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $220.00K derived: sum of 2 quarters · filed 2026-03-30 | $149.00K derived: sum of 3 quarters · filed 2026-03-30 | $81.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$143.00K derived: sum of 2 quarters · filed 2025-11-10 | -$211.00K 10-Q · filed 2025-11-10 | -$251.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$139.00K 10-Q · filed 2025-08-12 | -$179.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$68.00K 10-Q · filed 2025-05-13 | -$108.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$47.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$7.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |